Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial.

Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI.

Biol Psychiatry. 2008 Sep 1;64(5):361-8. doi: 10.1016/j.biopsych.2008.03.004. Epub 2008 Apr 23.

PMID:
18436195
2.

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.

Olié JP, Spina E, Murray S, Yang R.

Int Clin Psychopharmacol. 2006 May;21(3):143-51.

PMID:
16528136
3.

N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial.

Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI.

Biol Psychiatry. 2008 Sep 15;64(6):468-75. doi: 10.1016/j.biopsych.2008.04.022. Epub 2008 Jun 5.

PMID:
18534556
4.
5.

Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial.

Iancu I, Tschernihovsky E, Bodner E, Piconne AS, Lowengrub K.

Psychiatry Res. 2010 Aug 30;179(1):19-23. doi: 10.1016/j.psychres.2010.04.035. Epub 2010 May 15.

PMID:
20472299
6.

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.

Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A.

J Clin Psychiatry. 2009 Jun;70(6):829-36. doi: 10.4088/JCP.08m04905. Epub 2009 Jun 2.

PMID:
19497249
7.

Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.

Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD.

J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S29-35. doi: 10.1097/JCP.0b013e318169cca7.

PMID:
18334910
8.

Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial.

Sepehrmanesh Z, Heidary M, Akasheh N, Akbari H, Heidary M.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:289-296. doi: 10.1016/j.pnpbp.2017.11.001. Epub 2017 Nov 7.

PMID:
29126981
9.

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.

Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD.

J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S20-8. doi: 10.1097/JCP.0b013e318169d4ce.

PMID:
18334909
11.

Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.

Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A.

Biol Psychiatry. 2007 Dec 15;62(12):1363-70. Epub 2007 Jun 28.

PMID:
17601495
12.

Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.

Ratner Y, Gibel A, Yorkov V, Ritsner MS.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1401-9. Epub 2007 Jun 21.

PMID:
17669574
13.

Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.

Lawson WB, Herman BK, Loebel A, Lazariciu I, Malik M.

CNS Spectr. 2009 Sep;14(9):478-86.

PMID:
19890230
14.

Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.

Akhondzadeh S, Safarcherati A, Amini H.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):253-9. Epub 2004 Dec 28.

PMID:
15694232
15.

Regarding "N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial".

Hashimoto K.

Biol Psychiatry. 2008 Nov 1;64(9):e1. doi: 10.1016/j.biopsych.2008.06.025. Epub 2008 Aug 21. No abstract available.

PMID:
18718574
16.

Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study.

Jockers-Scherübl MC, Bauer A, Godemann F, Reischies FM, Selig F, Schlattmann P.

Int Clin Psychopharmacol. 2005 Jan;20(1):27-31.

PMID:
15602113
17.

Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.

Berk M, Gama CS, Sundram S, Hustig H, Koopowitz L, D'Souza R, Malloy H, Rowland C, Monkhouse A, Monkhouse A, Bole F, Sathiyamoorthy S, Piskulic D, Dodd S.

Hum Psychopharmacol. 2009 Apr;24(3):233-8. doi: 10.1002/hup.1017.

PMID:
19330802
18.

Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

Amiri A, Noorbala AA, Nejatisafa AA, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Hajiazim M, Raznahan M, Akhondzadeh S.

Hum Psychopharmacol. 2008 Mar;23(2):79-86.

PMID:
17972359
19.
20.

N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.

Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SM, Moghadam M, Gharibi F, Mirshafiee O, Akhondzadeh S.

Clin Neuropharmacol. 2013 Nov-Dec;36(6):185-92. doi: 10.1097/WNF.0000000000000001.

PMID:
24201233

Supplemental Content

Support Center